GlassScriptPhysician profile
Surabhi Ranjan
NPI 1194085332
$2,391.40
in general payments reported to CMS, 2019-2025
25 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $19.00 · 2021: $220 · 2022: $415 · 2023: $194 · 2024: $793 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $770.05 | 2019-2023 | Optune |
| Icotec Medical INC. | $293.24 | 2024 | Icotec Blackarmor Spine System |
| Zoll Respicardia, INC. | $148.16 | 2025 | Remede System |
| Depuy Synthes Sales INC. | $117.08 | 2022 | |
| Abbvie INC. | $116.96 | 2024-2025 | |
| Ucb, INC. | $102.78 | 2025 | Nayzilam, Rystiggo, Briviact |
| Merz Pharmaceuticals, LLC | $84.87 | 2023-2024 | Xeomin |
| Emd Serono, INC. | $84.70 | 2022-2025 | |
| Tg Therapeutics, INC. | $77.53 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.17 | 2023-2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $69.21 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $64.09 | 2023-2024 | Ingrezza, Ongentys |
| Neurelis, INC. | $58.58 | 2024-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $53.22 | 2025 | |
| Lilly USA, LLC | $49.87 | 2024 | Amyvid, Kisunla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48.91 | 2023-2025 | Wainua |
| Livanova USA, INC. | $31.78 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $25.05 | 2025 | |
| Omniscient Neurotechnology America LTD | $25.05 | 2023 | Quicktome |
| Boston Scientific Corporation | $21.41 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Epkinly, Imbruvica |
| Pfizer INC. | $19.64 | 2025 | |
| Acorda Therapeutics, INC | $19.19 | 2024 | Inbrija |
| Eisai INC. | $16.03 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Ranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.